The extent of the heterogeneity of the TIME in primary and metastatic NSCLC and the role of mTOR/EGFR/YAP1/MAP2K1 in modulating the interplay of the TIME remains poorly characterized. The gene discussed is MAP2K1; the disease is non-small cell lung carcinoma.